Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, Tenofovir

Brookie M. Best, Scott L. Letendre, Peter Koopmans, Steven S. Rossi, David B. Clifford, Ann C. Collier, Benjamin Gelman, Christina M. Marra, Justin C. McArthur, J. Allen McCutchan, Susan Morgello, David M. Simpson, Edmund V. Capparelli, Ronald J. Ellis, Igor Grant

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: Tenofovir is a nucleotide HIV reverse transcriptase inhibitor whose chemical properties suggest that it may not penetrate into the central nervous system in therapeutic concentrations. The study's objective was to determine tenofovir's penetration into cerebrospinal fluid (CSF). Methods: CNS HIV Antiretroviral Therapy Effects Research is a multicenter observational study to determine the effects of antiretroviral therapy on HIV-associated neurological disease. Single random plasma and CSF samples were drawn within an hour of each other from subjects taking tenofovir between October 2003 and March 2007. All samples were assayed by mass spectrometry with a detection limit of 0.9 ng/mL. Results: One hundred eighty-three participants (age 44 ± 8 years; 83 ± 32 kg; 33 females; CSF protein 44 ± 16 mg/dL) had plasma and CSF samples drawn 12.2 ± 6.9 and 11 ± 7.8 hours post dose, respectively. Median plasma and CSF tenofovir concentrations were 96 ng/mL [interquartile range (IQR) 47-153 ng/mL] and 5.5 ng/mL (IQR 2.7-11.3 ng/mL), respectively. Thirty-four of 231 plasma (14.7%) and 9 of 77 CSF samples (11.7%) were below detection. CSF to plasma concentration ratio from paired samples was 0.057 (IQR 0.03-0.1; n = 38). Median CSF to wild-type 50% inhibitory concentration ratio was 0.48 (IQR 0.24-0.98). Seventy-seven percent of CSF concentrations were below the tenofovir wild-type 50% inhibitory concentration. More subjects had detectable CSF HIV with lower (≤7 ng/mL) versus higher (>7ng/mL) CSF tenofovir concentrations (29% versus 9%; P = 0.05). Conclusions: Tenofovir concentrations in the CSF are only 5% of plasma concentrations, suggesting limited transfer into the CSF, and possibly active transport out of the CSF. CSF tenofovir concentrations may not effectively inhibit viral replication in the CSF.

Original languageEnglish (US)
Pages (from-to)376-381
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume59
Issue number4
DOIs
StatePublished - Apr 1 2012

Fingerprint

Tenofovir
HIV Reverse Transcriptase
Reverse Transcriptase Inhibitors
Cerebrospinal Fluid
Nucleotides
HIV
Inhibitory Concentration 50

Keywords

  • CSF
  • Pharmacokinetics
  • Tenofovir

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Best, B. M., Letendre, S. L., Koopmans, P., Rossi, S. S., Clifford, D. B., Collier, A. C., ... Grant, I. (2012). Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, Tenofovir. Journal of Acquired Immune Deficiency Syndromes, 59(4), 376-381. https://doi.org/10.1097/QAI.0b013e318247ec54

Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, Tenofovir. / Best, Brookie M.; Letendre, Scott L.; Koopmans, Peter; Rossi, Steven S.; Clifford, David B.; Collier, Ann C.; Gelman, Benjamin; Marra, Christina M.; McArthur, Justin C.; McCutchan, J. Allen; Morgello, Susan; Simpson, David M.; Capparelli, Edmund V.; Ellis, Ronald J.; Grant, Igor.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 59, No. 4, 01.04.2012, p. 376-381.

Research output: Contribution to journalArticle

Best, BM, Letendre, SL, Koopmans, P, Rossi, SS, Clifford, DB, Collier, AC, Gelman, B, Marra, CM, McArthur, JC, McCutchan, JA, Morgello, S, Simpson, DM, Capparelli, EV, Ellis, RJ & Grant, I 2012, 'Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, Tenofovir', Journal of Acquired Immune Deficiency Syndromes, vol. 59, no. 4, pp. 376-381. https://doi.org/10.1097/QAI.0b013e318247ec54
Best, Brookie M. ; Letendre, Scott L. ; Koopmans, Peter ; Rossi, Steven S. ; Clifford, David B. ; Collier, Ann C. ; Gelman, Benjamin ; Marra, Christina M. ; McArthur, Justin C. ; McCutchan, J. Allen ; Morgello, Susan ; Simpson, David M. ; Capparelli, Edmund V. ; Ellis, Ronald J. ; Grant, Igor. / Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, Tenofovir. In: Journal of Acquired Immune Deficiency Syndromes. 2012 ; Vol. 59, No. 4. pp. 376-381.
@article{2eec5f9a6c2a4dfdbdc5e2779f77eb2b,
title = "Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, Tenofovir",
abstract = "Background: Tenofovir is a nucleotide HIV reverse transcriptase inhibitor whose chemical properties suggest that it may not penetrate into the central nervous system in therapeutic concentrations. The study's objective was to determine tenofovir's penetration into cerebrospinal fluid (CSF). Methods: CNS HIV Antiretroviral Therapy Effects Research is a multicenter observational study to determine the effects of antiretroviral therapy on HIV-associated neurological disease. Single random plasma and CSF samples were drawn within an hour of each other from subjects taking tenofovir between October 2003 and March 2007. All samples were assayed by mass spectrometry with a detection limit of 0.9 ng/mL. Results: One hundred eighty-three participants (age 44 ± 8 years; 83 ± 32 kg; 33 females; CSF protein 44 ± 16 mg/dL) had plasma and CSF samples drawn 12.2 ± 6.9 and 11 ± 7.8 hours post dose, respectively. Median plasma and CSF tenofovir concentrations were 96 ng/mL [interquartile range (IQR) 47-153 ng/mL] and 5.5 ng/mL (IQR 2.7-11.3 ng/mL), respectively. Thirty-four of 231 plasma (14.7{\%}) and 9 of 77 CSF samples (11.7{\%}) were below detection. CSF to plasma concentration ratio from paired samples was 0.057 (IQR 0.03-0.1; n = 38). Median CSF to wild-type 50{\%} inhibitory concentration ratio was 0.48 (IQR 0.24-0.98). Seventy-seven percent of CSF concentrations were below the tenofovir wild-type 50{\%} inhibitory concentration. More subjects had detectable CSF HIV with lower (≤7 ng/mL) versus higher (>7ng/mL) CSF tenofovir concentrations (29{\%} versus 9{\%}; P = 0.05). Conclusions: Tenofovir concentrations in the CSF are only 5{\%} of plasma concentrations, suggesting limited transfer into the CSF, and possibly active transport out of the CSF. CSF tenofovir concentrations may not effectively inhibit viral replication in the CSF.",
keywords = "CSF, Pharmacokinetics, Tenofovir",
author = "Best, {Brookie M.} and Letendre, {Scott L.} and Peter Koopmans and Rossi, {Steven S.} and Clifford, {David B.} and Collier, {Ann C.} and Benjamin Gelman and Marra, {Christina M.} and McArthur, {Justin C.} and McCutchan, {J. Allen} and Susan Morgello and Simpson, {David M.} and Capparelli, {Edmund V.} and Ellis, {Ronald J.} and Igor Grant",
year = "2012",
month = "4",
day = "1",
doi = "10.1097/QAI.0b013e318247ec54",
language = "English (US)",
volume = "59",
pages = "376--381",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, Tenofovir

AU - Best, Brookie M.

AU - Letendre, Scott L.

AU - Koopmans, Peter

AU - Rossi, Steven S.

AU - Clifford, David B.

AU - Collier, Ann C.

AU - Gelman, Benjamin

AU - Marra, Christina M.

AU - McArthur, Justin C.

AU - McCutchan, J. Allen

AU - Morgello, Susan

AU - Simpson, David M.

AU - Capparelli, Edmund V.

AU - Ellis, Ronald J.

AU - Grant, Igor

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Background: Tenofovir is a nucleotide HIV reverse transcriptase inhibitor whose chemical properties suggest that it may not penetrate into the central nervous system in therapeutic concentrations. The study's objective was to determine tenofovir's penetration into cerebrospinal fluid (CSF). Methods: CNS HIV Antiretroviral Therapy Effects Research is a multicenter observational study to determine the effects of antiretroviral therapy on HIV-associated neurological disease. Single random plasma and CSF samples were drawn within an hour of each other from subjects taking tenofovir between October 2003 and March 2007. All samples were assayed by mass spectrometry with a detection limit of 0.9 ng/mL. Results: One hundred eighty-three participants (age 44 ± 8 years; 83 ± 32 kg; 33 females; CSF protein 44 ± 16 mg/dL) had plasma and CSF samples drawn 12.2 ± 6.9 and 11 ± 7.8 hours post dose, respectively. Median plasma and CSF tenofovir concentrations were 96 ng/mL [interquartile range (IQR) 47-153 ng/mL] and 5.5 ng/mL (IQR 2.7-11.3 ng/mL), respectively. Thirty-four of 231 plasma (14.7%) and 9 of 77 CSF samples (11.7%) were below detection. CSF to plasma concentration ratio from paired samples was 0.057 (IQR 0.03-0.1; n = 38). Median CSF to wild-type 50% inhibitory concentration ratio was 0.48 (IQR 0.24-0.98). Seventy-seven percent of CSF concentrations were below the tenofovir wild-type 50% inhibitory concentration. More subjects had detectable CSF HIV with lower (≤7 ng/mL) versus higher (>7ng/mL) CSF tenofovir concentrations (29% versus 9%; P = 0.05). Conclusions: Tenofovir concentrations in the CSF are only 5% of plasma concentrations, suggesting limited transfer into the CSF, and possibly active transport out of the CSF. CSF tenofovir concentrations may not effectively inhibit viral replication in the CSF.

AB - Background: Tenofovir is a nucleotide HIV reverse transcriptase inhibitor whose chemical properties suggest that it may not penetrate into the central nervous system in therapeutic concentrations. The study's objective was to determine tenofovir's penetration into cerebrospinal fluid (CSF). Methods: CNS HIV Antiretroviral Therapy Effects Research is a multicenter observational study to determine the effects of antiretroviral therapy on HIV-associated neurological disease. Single random plasma and CSF samples were drawn within an hour of each other from subjects taking tenofovir between October 2003 and March 2007. All samples were assayed by mass spectrometry with a detection limit of 0.9 ng/mL. Results: One hundred eighty-three participants (age 44 ± 8 years; 83 ± 32 kg; 33 females; CSF protein 44 ± 16 mg/dL) had plasma and CSF samples drawn 12.2 ± 6.9 and 11 ± 7.8 hours post dose, respectively. Median plasma and CSF tenofovir concentrations were 96 ng/mL [interquartile range (IQR) 47-153 ng/mL] and 5.5 ng/mL (IQR 2.7-11.3 ng/mL), respectively. Thirty-four of 231 plasma (14.7%) and 9 of 77 CSF samples (11.7%) were below detection. CSF to plasma concentration ratio from paired samples was 0.057 (IQR 0.03-0.1; n = 38). Median CSF to wild-type 50% inhibitory concentration ratio was 0.48 (IQR 0.24-0.98). Seventy-seven percent of CSF concentrations were below the tenofovir wild-type 50% inhibitory concentration. More subjects had detectable CSF HIV with lower (≤7 ng/mL) versus higher (>7ng/mL) CSF tenofovir concentrations (29% versus 9%; P = 0.05). Conclusions: Tenofovir concentrations in the CSF are only 5% of plasma concentrations, suggesting limited transfer into the CSF, and possibly active transport out of the CSF. CSF tenofovir concentrations may not effectively inhibit viral replication in the CSF.

KW - CSF

KW - Pharmacokinetics

KW - Tenofovir

UR - http://www.scopus.com/inward/record.url?scp=84859744786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859744786&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e318247ec54

DO - 10.1097/QAI.0b013e318247ec54

M3 - Article

VL - 59

SP - 376

EP - 381

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 4

ER -